Sign In
Buy SIOX
$0.478
+0 (+0%)
At Close: May 06, 2024
SIOX Stock Price Increases Over 15% Pre-Market: Why It Happened
04:43am, Tuesday, 15'th Jun 2021
The stock price of Sio Gene Therapies Inc (NASDAQ: SIOX) increased by over 15% pre-market. This is why it happened.
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones
07:00am, Wednesday, 09'th Jun 2021
– Multiple GM1 gangliosidosis program milestones expected in FY2021, including 12-month data updates from the ongoing dose-escalation study and meeting with FDA to align on registrational pathway
Sio Gene Therapies: Gene Therapies For Neurodegeneration
12:30am, Friday, 28'th May 2021
Sio Gene Therapies: Gene Therapies For Neurodegeneration
Are Options Traders Betting on a Big Move in Sio Gene Therapies (SIOX) Stock?
09:46am, Tuesday, 25'th May 2021
Investors need to pay close attention to Sio Gene Therapies (SIOX) stock based on the movements in the options market lately.
3 Robinhood Penny Stocks Under $2 to Watch Next Week
01:54pm, Saturday, 22'nd May 2021
Best Robinhood penny stocks to buy? Check these 3 out for your watchlist The post 3 Robinhood Penny Stocks Under $2 to Watch Next Week appeared first on Penny Stocks to Buy, Picks, News and Informatio
Sio Gene Therapies: A Speculative Buy For Their Undervalued Gene Therapies
02:18pm, Sunday, 16'th May 2021
On May 13, SIOX announced that their AAV9 gene therapy shows beneficial effects in GM1 gangliosidosis, a fatal pediatric genetic disorder. SIOX states that this data represents the first direct eviden
Sio Gene Therapies' GM1 Gangliosidosis Gene Therapy Candidate Shows Substrate Reduction In CSF
09:16am, Thursday, 13'th May 2021
Sio Gene Therapies Inc (NASDAQ: SIOX) has announced new biomarker data from Phase 1/2 study of AXO-AAV-GM1, an adeno-associated viral vector (AAV)9-based gene therapy candidate for GM1 gangliosi
7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts
03:45pm, Wednesday, 12'th May 2021
Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts ap
Week 18 MDA Breakout Stocks - May 2021: Short-Term Picks To Give You An Edge
01:02pm, Saturday, 01'st May 2021
Week 18 MDA Breakout Stocks - May 2021: Short-Term Picks To Give You An Edge
Sio Gene Therapies Announces Four Upcoming Oral Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy
07:00am, Wednesday, 28'th Apr 2021
NEW YORK, and RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transf
Sio Gene Therapies to Participate in Upcoming Conferences
08:00am, Monday, 29'th Mar 2021
NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve
Why I've Taken A Position In Sio Gene Therapies
01:06pm, Monday, 08'th Mar 2021
SIOX has promising results in its gene therapy programs. Not only is the Parkinson's disease program showing impressive results, but recent developments on the rare disease front are also very encoura
Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference
07:00am, Tuesday, 16'th Feb 2021
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve
Dosing Underway In Sio Gene's Early-Stage Trial For GM2 Gangliosidosis Gene Therapy
11:49am, Wednesday, 03'rd Feb 2021
Sio Gene Therapies Inc (NASDAQ: SIOX) has dosed the first patient in Phase 1/2 trial evaluating AXO-AAV-GM2 investigational gene therapy to treat GM2 gangliosidosis, also known as Tay-Sachs or Sandhof
- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies - Expect to continue patient identification, screening, and enrollment in Stage 1 of the study throu
